Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS
Content archived on 2024-04-30

In vitro system for enhanced and tumor specific graft versus leukemia effect provided by tumor antigen specific donor cytotoxic t lymphocytes

Objective



Allogeneic bone marrow transplantation for the treatment of leukemia in patients with acute lymphocytic leukemia (ALL) is used with increasing frequency. However, one of the major shortcomings remains the risk of leukemic relapse. In ALL of mature T-cells (T-ALL) the variable region of the T-cell receptor (VB) is unique for all monoclonal tumor cells, thus representing a 'tumor defining antigen'. In order to induce a graft-versus-leukemia reaction directed specifically against these tumor cells, HLA-matched, CD8+ T-cells will be primed in vitro by autologous dendritic cells presenting recombinant VB tumor antigen. In vitro primed cytotoxic CD8+ T-cells will subsequently be tested for their ability to specifically kill the T-ALL cells from which the recombinant VB was derived. If so, this in vitro model would open new avenues in the protection from leukemic relapse of T-ALL patients after allogeneic bone marrow transplantation.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Call for proposal

Data not available

Funding Scheme

RGI - Research grants (individual fellowships)

Coordinator

Albert-Ludwigs-Universität Freiburg
EU contribution
No data
Address
55,Hugstetter Straße
79106 Freiburg
Germany
Total cost
No data

Participants (1)